Can Exenatide Prevent Glucocorticoid- Induced Hyperglycemia?

Kuritzky, Louis
March 2011
Internal Medicine Alert;3/15/2011 Supplement, p39
The article reports on a study which reveals that the concomitant administration of exenatide (EXE) placebo could help prevent glucocorticoid-induced hyperglycemia (GIH).


Related Articles

  • Topiramate in migraine prophylaxis: data from a pooled analysis and open-label extension study. Bussone, G.; Usai, S.; D'Amico, D. // Neurological Sciences;May2006 Supplement 2, Vol. 27, ps159 

    Topiramate is approved for the preventive treatment of migraine in several countries based on the results of three large randomised, double-blind studies that showed that this compound was significantly more effective than placebo in migraine prophylaxis. We review the results of two studies:...

  • The influence of placebo awareness on stimulant drug response in a double-blind trial. Nash, Justin M.; Holroyd, Kenneth A.; Rokicki, Lori A.; Kvaal, Steven; Penzien, Donald B. // Psychopharmacology;2002, Vol. 161 Issue 3, p213 

    Presents information on a study which determined whether drug administration instructions informing subjects of a placebo condition affect the drug response and affect the saliva concentration of the stimulant. Methodology; Results and discussion; Conclusions.

  • A cluster-randomized trial of mass drug administration with a gametocytocidal drug combination to interrupt malaria transmission in a low endemic area in Tanzania.  // Malaria Journal;2011, Vol. 10 Issue 1, p247 

    The article discusses a study which carried out a cluster-randomized trial of mass drug administration (MDA) with a gametocytocidal drug combination to interrupt malaria transmission in a low endemic area in Tanzania. As part of the study, eight clusters were randomized to observed treatment...

  • Letters. Speers, Robert; Barclay, Mark; Gerber, Irving // Drug Topics;Dec2010, Vol. 154 Issue 12, p10 

    Several letters to the editor are presented related to placebos including the refilling of capsules with placebos, the giving of saccharin tablets as placebos, and a response to the previous article "When to Lie," in the November 2010 issue.

  • Acquisition and extinction of conditioned nicotine analgesic tolerance. Azorlosa, Julian I.; Johnson, Carolyn E.; McConnell, James J. // Learning & Behavior;Aug2006, Vol. 34 Issue 3, p262 

    These studies demonstrated the acquisition and extinction of conditioned tolerance to the analgesic effect of nicotine in rats. In Experiment 1, distinctive environmental cues were either paired or unpaired with nicotine. Following acquisition, the paired group was more tolerant to nicotine than...

  • The Placebo Effect: Belief and Healing. Nordenberg, Tamar // Consumers' Research Magazine;Feb2000, Vol. 83 Issue 2, p16 

    Deals with the use of placebo-controlled drug studies. Examples of studies featuring the placebo effect; Stance of the United State Food and Drug Administration (FDA) on the drug study; Comments from Robert DeLap of the FDA Offices of Drug Evaluation. INSET: Doctors' Use of Placebos: Opposing...

  • The Acute Haemodynamic Effect of Nebulised Frusemide in Stable, Advanced Heart Failure Newton, Phillip J.; Davidson, Patricia M.; Krum, Henry; Ollerton, Richard; Macdonald, Peter // Heart, Lung & Circulation;May2012, Vol. 21 Issue 5, p260 

    Purpose: To assess the acute haemodynamic effects of nebulised frusemide in a stable advanced heart failure population. Procedure: In this randomised, double blind, placebo controlled trial, people with stable, advanced heart failure undergoing right heart catheterisation were randomised to...

  • Low-Dose Penicillin Prevents Recurrent Cellulitis. EBELL, MARK H. // American Family Physician;11/1/2013, Vol. 88 Issue 9, p608 

    The article discusses the study "Penicillin to Prevent Recurrent Leg Cellulitis," conducted by K. S. Thomas and colleagues, and published in a 2013 issue of "The New England Journal of Medicine." The study investigated effectiveness of low-dose penicillin in preventing cellulitis of the leg. It...

  • First Chemokine Receptor Antagonist Available Under Expanded Access. Winslow, Dean L. // Infectious Disease Alert;Feb2007, Vol. 26 Issue 5, p50 

    UK-427,857 (MARAVIROC) IS AN INVESTIGATIONAL small-molecule HIV entry inhibitor that binds to the CCR5 chemokine receptor on the surface of T-cells. This chemokine receptor is normally the receptor for the chemokines MIP-1 alpha and RANTES. In HIV infection after initial binding of HIV's...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics